nevirapine has been researched along with Body Weight in 25 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We report the bioavailability and short-term safety of a novel paediatric FDC tablet of zidovudine (ZDV)/lamivudine (3TC)/nevirapine (NVP; 30/15/28 mg) in HIV-infected children." | 9.15 | Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. ( Aurpibul, L; Capparelli, E; Chokephaibulkit, K; Cressey, TR; Eksaengsri, A; Hongsiriwon, S; Kabat, B; Limwongse, C; McIntosh, K; Muresan, P; Ngampiyaskul, C; Sirisanthana, V; Smith, ME; Toye, M; Wittawatmongkol, O; Yogev, R, 2011) |
| "The aim of this study was to evaluate the pharmacokinetics of lamivudine (3TC), stavudine (d4T) and nevirapine (NVP) in HIV-infected Malawian children receiving quartered tablet multiples of Triomune 40 (generic tablet [GT]) compared with individual generic liquid (GL) and trade liquid (TL)." | 9.14 | Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children. ( Corbett, AH; Hosseinipour, MC; Kanyama, C; Kashuba, AD; Kazembe, P; Mkupani, P; Mwansambo, C; Nyirenda, J; Rezk, NL; Sichali, D; Tien, H; Weigel, R, 2010) |
| "Nevirapine (NVP) is an antiretroviral medication that prevents human immunodeficiency virus (HIV) cells from multiplying in the blood." | 5.38 | Chronic administration of the antiretroviral nevirapine increases body weight, food, and water intake in albino Wistar rats. ( Obembe, AO; Osim, EE; Umoren, EB, 2012) |
| "The median [interquartile range (IQR)] age, body weight and daily nevirapine dose in 15 included children (eight girls) were 4." | 5.16 | Pharmacokinetics of nevirapine in HIV-infected infants weighing 3 kg to less than 6 kg taking paediatric fixed dose combination tablets. ( Burger, DM; Chintu, C; Cook, A; Ferrier, A; Fillekes, Q; Gibb, DM; Kabamba, D; Kankasa, C; Mulenga, V; Thomason, MJ; Walker, AS, 2012) |
| " We report the bioavailability and short-term safety of a novel paediatric FDC tablet of zidovudine (ZDV)/lamivudine (3TC)/nevirapine (NVP; 30/15/28 mg) in HIV-infected children." | 5.15 | Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. ( Aurpibul, L; Capparelli, E; Chokephaibulkit, K; Cressey, TR; Eksaengsri, A; Hongsiriwon, S; Kabat, B; Limwongse, C; McIntosh, K; Muresan, P; Ngampiyaskul, C; Sirisanthana, V; Smith, ME; Toye, M; Wittawatmongkol, O; Yogev, R, 2011) |
| "The aim of this study was to evaluate the pharmacokinetics of lamivudine (3TC), stavudine (d4T) and nevirapine (NVP) in HIV-infected Malawian children receiving quartered tablet multiples of Triomune 40 (generic tablet [GT]) compared with individual generic liquid (GL) and trade liquid (TL)." | 5.14 | Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children. ( Corbett, AH; Hosseinipour, MC; Kanyama, C; Kashuba, AD; Kazembe, P; Mkupani, P; Mwansambo, C; Nyirenda, J; Rezk, NL; Sichali, D; Tien, H; Weigel, R, 2010) |
| " The objective of this study was to assess the impact of body weight on the pharmacokinetic disposition of nelfinavir (NFV) in the absence and presence of nevirapine (NVP) and compare the pharmacokinetic profiles of twice-daily (BID) and three-times-daily (TID) NFV regimens." | 5.10 | Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377. ( Aweeka, FT; Floren, LC; Hayashi, S; Jayewardene, A; Johnson, G; Krogstad, P; Nachman, S; Stanley, K; Wiznia, A, 2003) |
| " Simulations of the nevirapine concentration profile were performed with dosing regimens of 200 mg twice daily and 400 mg once daily for individuals with body weights of 50, 70 and 90 kg in combination with CYP2B6 genetic variation." | 3.77 | Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. ( Back, DJ; Brockmeyer, NH; Davies, G; Egan, D; Fätkenheuer, G; Hendra, H; Johnson, MA; Khoo, S; Mahungu, T; Owen, A; Rockstroh, J; Schipani, A; Siccardi, M; Wyen, C; Youle, M, 2011) |
| " However, long-term use poses adherence challenges, is associated with metabolic toxic effects, restricts second-line options, and is costly." | 2.77 | Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. ( Abrams, EJ; Coovadia, A; Hu, CC; Hunt, G; Kuhn, L; Martens, L; Meyers, T; Morris, L; Persaud, D; Sherman, G; Strehlau, R; Tsai, WY, 2012) |
| "Patients with Acquired Immunodeficiency Syndrome (AIDS) were recruited under the Federal Government Highly Active Antiretroviral Therapy (HAART) programme at the University of Ilorin Teaching Hospital." | 2.73 | Effect of highly active antiretroviral therapy on CD4 count and weight in AIDS patients seen at the UITH, Ilorin. ( Iseniyi, JO; Odeigah, L; Olatunji, PO; Olawumi, HO; Salami, AK, 2008) |
| "Nevirapine C12h was subtherapeutic (< 3." | 2.73 | Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. ( Burger, DM; Chintu, C; Ewings, FM; Gibb, DM; Kabamba, D; Kankasa, C; L'homme, RF; Mulenga, V; Thomason, MJ; Walker, AS, 2008) |
| "Body weight was measured in kilograms with light clothes on." | 2.72 | The value of serum albumin in pretreatment assessment and monitoring of therapy in HIV/AIDS patients. ( Olatunji, PO; Olawumi, HO, 2006) |
| " Adjusting dosage by means of therapeutic drug monitoring would appear to be a reasonable way of maximising patient benefit from treatment." | 2.71 | Follow-up measurements of Nevirapine plasma levels over a prolonged period. ( Ebigbo, A; Klinker, H; Knipper, A; Langmann, P; Sienz, M; Winzer, R; Zilly, M, 2004) |
| " Mice were dosed twice daily until PND 28." | 1.39 | Toxicology and Carcinogenesis Studies of Mixtures of 3'-Azido-3'-Deoxythymidine (AZT), Lamivudine (3TC), and Nevirapine (NVP) (CAS Nos. 30516-87-1, 134678-17-4, 129618-40-2) in Genetically Modified C3B6.129F1-Trp53(tm1Brd) N12 Haploinsufficient Mice (in u ( , 2013) |
| "By logistic regression, history of drug allergy (OR, 3." | 1.35 | Risk factors for nevirapine-associated rash among HIV-infected patients with low CD4 cell counts in resource-limited settings. ( Chantratita, W; Charoenyingwattana, A; Kiertiburanakul, S; Mahasirimongkol, S; Sungkanuparph, S; Sura, T, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (40.00) | 29.6817 |
| 2010's | 14 (56.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X | 1 |
| Ding, L | 1 |
| Tao, Y | 1 |
| Pannecouque, C | 1 |
| De Clercq, E | 1 |
| Zhuang, C | 1 |
| Chen, FE | 1 |
| Patel, RC | 1 |
| Jakait, B | 1 |
| Thomas, K | 1 |
| Yiannoutsos, C | 1 |
| Onono, M | 1 |
| Bukusi, EA | 1 |
| Wools-Kaloustian, KK | 1 |
| Cohen, CR | 1 |
| Owor, M | 1 |
| Mwatha, A | 1 |
| Donnell, D | 1 |
| Musoke, P | 1 |
| Mmiro, F | 1 |
| Allen, M | 1 |
| Jackson, JB | 1 |
| Fowler, MG | 2 |
| Guay, LA | 1 |
| Mir, F | 1 |
| Qamar, FN | 1 |
| Baig-Ansari, N | 1 |
| Abro, AG | 1 |
| Abbas, SQ | 1 |
| Kazi, MA | 1 |
| Rizvi, A | 1 |
| Zaidi, AK | 1 |
| Izudi, J | 1 |
| Alioni, S | 1 |
| Kerukadho, E | 1 |
| Ndungutse, D | 1 |
| Stöhr, W | 1 |
| Back, D | 1 |
| Dunn, D | 1 |
| Sabin, C | 1 |
| Winston, A | 1 |
| Gilson, R | 1 |
| Pillay, D | 1 |
| Hill, T | 1 |
| Ainsworth, J | 1 |
| Pozniak, A | 1 |
| Leen, C | 1 |
| Bansi, L | 1 |
| Fisher, M | 1 |
| Orkin, C | 1 |
| Anderson, J | 1 |
| Johnson, M | 1 |
| Easterbrook, P | 1 |
| Gibbons, S | 1 |
| Khoo, S | 2 |
| Olawumi, HO | 2 |
| Olatunji, PO | 2 |
| Salami, AK | 1 |
| Odeigah, L | 1 |
| Iseniyi, JO | 1 |
| Munderi, P | 1 |
| Walker, AS | 3 |
| Kityo, C | 1 |
| Babiker, AG | 1 |
| Ssali, F | 1 |
| Reid, A | 1 |
| Darbyshire, JH | 1 |
| Grosskurth, H | 1 |
| Mugyenyi, P | 1 |
| Gibb, DM | 3 |
| Gilks, CF | 1 |
| Corbett, AH | 1 |
| Hosseinipour, MC | 1 |
| Nyirenda, J | 1 |
| Kanyama, C | 1 |
| Rezk, NL | 1 |
| Mkupani, P | 1 |
| Sichali, D | 1 |
| Tien, H | 1 |
| Kashuba, AD | 1 |
| Mwansambo, C | 1 |
| Weigel, R | 1 |
| Kazembe, P | 1 |
| Venkatesh, KK | 1 |
| Lurie, MN | 1 |
| Triche, EW | 1 |
| De Bruyn, G | 1 |
| Harwell, JI | 1 |
| McGarvey, ST | 1 |
| Gray, GE | 1 |
| Schipani, A | 1 |
| Wyen, C | 1 |
| Mahungu, T | 1 |
| Hendra, H | 1 |
| Egan, D | 1 |
| Siccardi, M | 1 |
| Davies, G | 1 |
| Fätkenheuer, G | 1 |
| Youle, M | 1 |
| Rockstroh, J | 1 |
| Brockmeyer, NH | 1 |
| Johnson, MA | 1 |
| Owen, A | 1 |
| Back, DJ | 1 |
| Chokephaibulkit, K | 1 |
| Cressey, TR | 1 |
| Capparelli, E | 1 |
| Sirisanthana, V | 1 |
| Muresan, P | 1 |
| Hongsiriwon, S | 1 |
| Ngampiyaskul, C | 1 |
| Limwongse, C | 1 |
| Wittawatmongkol, O | 1 |
| Aurpibul, L | 1 |
| Kabat, B | 1 |
| Toye, M | 1 |
| Smith, ME | 1 |
| Eksaengsri, A | 1 |
| McIntosh, K | 1 |
| Yogev, R | 1 |
| Kuhn, L | 1 |
| Coovadia, A | 1 |
| Strehlau, R | 1 |
| Martens, L | 1 |
| Hu, CC | 1 |
| Meyers, T | 1 |
| Sherman, G | 1 |
| Hunt, G | 1 |
| Persaud, D | 1 |
| Morris, L | 1 |
| Tsai, WY | 1 |
| Abrams, EJ | 1 |
| Fillekes, Q | 1 |
| Mulenga, V | 2 |
| Kabamba, D | 2 |
| Kankasa, C | 2 |
| Thomason, MJ | 2 |
| Cook, A | 1 |
| Ferrier, A | 1 |
| Chintu, C | 2 |
| Burger, DM | 2 |
| Umoren, EB | 1 |
| Obembe, AO | 1 |
| Osim, EE | 1 |
| Barlow-Mosha, LN | 1 |
| Bagenda, DS | 1 |
| Mudiope, PK | 1 |
| Mubiru, MC | 1 |
| Butler, LM | 1 |
| Musoke, PM | 1 |
| Floren, LC | 1 |
| Wiznia, A | 1 |
| Hayashi, S | 1 |
| Jayewardene, A | 1 |
| Stanley, K | 1 |
| Johnson, G | 1 |
| Nachman, S | 1 |
| Krogstad, P | 1 |
| Aweeka, FT | 1 |
| Sienz, M | 1 |
| Zilly, M | 1 |
| Ebigbo, A | 1 |
| Knipper, A | 1 |
| Winzer, R | 1 |
| Klinker, H | 1 |
| Langmann, P | 1 |
| Tin, EE | 1 |
| Bowonwatanuwong, C | 1 |
| Desakorn, V | 1 |
| Wilairatana, P | 1 |
| Krudsood, S | 1 |
| Pitisuttithum, P | 1 |
| Saghayam, S | 1 |
| Kumarasamy, N | 1 |
| Cecelia, AJ | 1 |
| Solomon, S | 1 |
| Mayer, K | 1 |
| Wanke, C | 1 |
| Song, R | 1 |
| Jelagat, J | 1 |
| Dzombo, D | 1 |
| Mwalimu, M | 1 |
| Mandaliya, K | 1 |
| Shikely, K | 1 |
| Essajee, S | 1 |
| Kiertiburanakul, S | 1 |
| Sungkanuparph, S | 1 |
| Charoenyingwattana, A | 1 |
| Mahasirimongkol, S | 1 |
| Sura, T | 1 |
| Chantratita, W | 1 |
| L'homme, RF | 1 |
| Ewings, FM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Relevance of Nevirapine Resistance[NCT00117728] | Phase 3 | 250 participants (Anticipated) | Interventional | 2005-04-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 trials available for nevirapine and Body Weight
| Article | Year |
|---|---|
Long-term follow-up of children in the HIVNET 012 perinatal HIV prevention trial: five-year growth and survival.
Topics: Anthropometry; Anti-HIV Agents; Body Height; Body Weight; Chemoprevention; Child, Preschool; Female; | 2013 |
Effect of highly active antiretroviral therapy on CD4 count and weight in AIDS patients seen at the UITH, Ilorin.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy | 2008 |
Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
Topics: Adult; Body Weight; CD4 Lymphocyte Count; Dideoxynucleosides; Disease Progression; Double-Blind Meth | 2010 |
Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children.
Topics: Adolescent; Anti-HIV Agents; Body Weight; Child; Child, Preschool; Cross-Over Studies; Dosage Forms; | 2010 |
Growth of infants born to HIV-infected women in South Africa according to maternal and infant characteristics.
Topics: Adult; Anti-HIV Agents; Body Height; Body Weight; CD4 Lymphocyte Count; Epidemiologic Methods; Femal | 2010 |
Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.
Topics: Anti-HIV Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biological Availability; Body Weig | 2011 |
Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial.
Topics: Alanine Transaminase; Anti-HIV Agents; Body Height; Body Weight; Chi-Square Distribution; Child, Pre | 2012 |
Pharmacokinetics of nevirapine in HIV-infected infants weighing 3 kg to less than 6 kg taking paediatric fixed dose combination tablets.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Weight; Drug Administration Schedule; D | 2012 |
Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Antiretroviral Therapy, Highly Active; Biological Av | 2003 |
Follow-up measurements of Nevirapine plasma levels over a prolonged period.
Topics: Anti-HIV Agents; Body Weight; Drug Monitoring; Female; Follow-Up Studies; HIV; HIV Infections; Human | 2004 |
The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients.
Topics: Adolescent; Adult; Age Factors; Aged; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antire | 2005 |
The value of serum albumin in pretreatment assessment and monitoring of therapy in HIV/AIDS patients.
Topics: Adult; Anti-HIV Agents; Body Weight; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Lamivudin | 2006 |
Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets.
Topics: Adolescent; Antiretroviral Therapy, Highly Active; Area Under Curve; Body Weight; Child; Child, Pres | 2008 |
12 other studies available for nevirapine and Body Weight
| Article | Year |
|---|---|
Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
Topics: Animals; Anti-HIV Agents; Body Weight; Cell Line; Cell Survival; Dose-Response Relationship, Drug; D | 2020 |
Increasing body mass index or weight does not appear to influence the association between efavirenz-based antiretroviral therapy and implant effectiveness among HIV-positive women in western Kenya.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Mass Index; Body Weight; Cohort Stud | 2019 |
Toxicology and Carcinogenesis Studies of Mixtures of 3'-Azido-3'-Deoxythymidine (AZT), Lamivudine (3TC), and Nevirapine (NVP) (CAS Nos. 30516-87-1, 134678-17-4, 129618-40-2) in Genetically Modified C3B6.129F1-Trp53(tm1Brd) N12 Haploinsufficient Mice (in u
Topics: Animals; Animals, Genetically Modified; Animals, Newborn; Anti-HIV Agents; Body Weight; Chemistry, P | 2013 |
Clinical manifestations and treatment outcomes in HIV-1-infected children receiving antiretroviral therapy in Karachi, Pakistan.
Topics: Anti-HIV Agents; Body Height; Body Weight; CD4 Lymphocyte Count; Child, Preschool; Drug Resistance, | 2014 |
Virological failure reduced with HIV-serostatus disclosure, extra baseline weight and rising CD4 cells among HIV-positive adults in Northwestern Uganda.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Weight; CD4-Positive T-Lymphocytes; Cohort Studi | 2016 |
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.
Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Black People; Body Weight; Cyc | 2008 |
Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Body Wei | 2011 |
Chronic administration of the antiretroviral nevirapine increases body weight, food, and water intake in albino Wistar rats.
Topics: Animals; Anti-HIV Agents; Body Weight; Drinking; Eating; Female; Male; Nevirapine; Rats; Rats, Wista | 2012 |
The long-term effectiveness of generic adult fixed-dose combination antiretroviral therapy for HIV-infected Ugandan children.
Topics: Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; CD4 Lymphocyte | 2012 |
Weight and body shape changes in a treatment-naive population after 6 months of nevirapine-based generic highly active antiretroviral therapy in South India.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; Body Weight; CD4 Ly | 2007 |
Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Weight; CD4 Lymphocyte Coun | 2007 |
Risk factors for nevirapine-associated rash among HIV-infected patients with low CD4 cell counts in resource-limited settings.
Topics: Adult; Body Weight; Case-Control Studies; CD4 Lymphocyte Count; Developing Countries; Drug Hypersens | 2008 |